P1319: TREATMENT WITH MIDOSTAURIN AND OTHER FLT3 TARGETING INHIBITORS IS ASSOCIATED WITH AN INCREASED RISK OF CARDIOVASCULAR ADVERSE EVENTS IN PATIENTS WITH FLT3 MUTATED AML WHO UNDERWENT ALLOGENEIC HCT

Detalles Bibliográficos
Autores principales: Cremer, Anjali, Enssle, Julius C., Pfaff, Saskia, Kouidri, Khouloud, Lang, Fabian, Brandts, Christian, Zeiher, Andreas, Cremer, Sebastian, Steffen, Björn, Serve, Hubert, Bug, Gesine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Posters
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10430512/
http://dx.doi.org/10.1097/01.HS9.0000972164.39454.e5
Descripción
Sumario:

Ejemplares similares